Multiple reliable and valid disease activities indices exist and have been used successfully in longitudinal studies. However, the definition of flare, using these intruments, has not been universally decided or accepted. Because flare is one of the three major patterns of lupus activity, it will remain an important outcome measure in both longitudinal and clinical trial studies.
Petri M , Barr SG , Zonana-Nach A , Magder L . Measures of disease activity, damage, and health status: the Hopkins Lupus Cohort Experience . J Rheum1999; 26: 502-503 .
2.
Glaman D , Ginzler E , Goldsmith C et al. Workshop Report. Systemic Lupus International Collaborative Clinics: development of a damage index in SLE . J Rheumatol1992; 19: 1820-1821 .
3.
Petri M , Hellmann D , Hochberg M . Validity and reliability of lupus activity measures in the routine clinic setting . J Rheumatol1992; 19: 53-59 .
4.
Hellmann DB , Petri M , Whiting-O'Keefe Q. Fatal infections in systemic lupus erythematosus: role of opportunistic organisms . Medicine1987; 66: 341-348 .
5.
Bombardier C , Gladman DD , Urowitz M et al. Derivation of the SLEDAI: a disease activity index for lupus patients . Arthritis Rheum1992; 35: 630-640 .
6.
Petri M , Genovese M , Engle E , Hochberg M . Definition, incidence and clinical description of flare in systemic lupus erythematosus: a prospective cohort study . Arthritis Rheum1991; 34: 937-944 .
7.
Swaak AJG , Nossent JC , Bronsveld W et al. Systemic lupus erythematosus. II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 110 patients studied prospectively . Ann Rheum Dis1989; 48: 455-460 .
8.
Hay EM , Bacon PA , Gordon C et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus . Q J Med1993; 86 (7): 447-458 .
9.
Stoll T , Stucki G , Malik J et al. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus . Ann Rheum Dis1996; 55 (10): 756-760 .
10.
Ehrenstein MR , Conroy SE , Heath J et al. The occurrence, nature and distribution of flares in a cohort of patients with systemic lupus erythematosus: a rheumatological view . Br J Rheumatol1995; 34 (3): 257-260 .
11.
Petri M , Magder L . Predictive value of anti-dsDNA for future SLE disease activity in patients who have had positive anti-dsDNA in the past [abstract] . Arthritis Rheum1998; 41, (No. 9 Suppl): S127-s127 .
12.
Esdaile JM , Abrahamowicz M , Joseph L et al. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail . Arthritis Rheum1996; 39: 370-378 .
ter Borg EJ , Horst G , Hummel EJ et al. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disese exacerbation in systemic lupus erythematosus: a long-term, prospective study . Arthritis Rheum1990; 33: 634-643 .
15.
Bootsma H , Spronk PE , ter Borg EJ et al. The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation . Ann Rheum Dis1997; 56: 661-666 .
16.
Spronk PE , Bootsma H , Kallenberg CG . Anti-DNA antibodies as early predictor for disease exacerbations in SLE. Cuideline for treatment?Clin Rev Allergy Immunol1998; 16: 211-218 .
17.
Buyon JP , Tamerius J , Belmont HM , Abramson SB . Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional mesurements of complement . Arthritis Rheum1992; 35: 1028-1037 .
18.
Kerr LD , Adelsberg BR , Schulman P , Spiera H . Factor B activation products in patients with systemic lupus erythematosus: a marker of severe disease activity . Arthritis Rheum1985; 32: 1406-1413 .
19.
Fitzgerald JD , Grossman JM , Kalunian KC . Annual systemic lupus erythematosus flare rates in university practice [abstract] . Arthritis Rheum1998; 41 (No. 9 Suppl): S219-S219 .
20.
Dvorkina O , Aranow C , Orloff K et al. SLE disease activity an flare rates in premenopausal women in an urban center [abstract] . Arthritis Rheum1998; 41 (No. 9 Suppl): S66-S66 .
21.
Kagal A , Gladman D , Urowitz MB . Describing disease activity in SLE over time [abstract] . Arthritis Rheum1998; 41 (No. 9 Suppl): S220-S220 .
22.
Fortin PR , Ferland D , Moore AD et al. Rates and predictors of lupus flares . Arthritis Rheum1998; 41 (No. 9 Suppl): S218-S218 .
23.
Boumpas DT , Austin III HA , Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis . Lancet1992; 340: 741-745 .
24.
Gourley MF , Austin III HA , Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial . Ann Intern Med1996; 125 (7): 549-557 .
25.
Liang MH , Socher SA , Larson MG , Schur PH . Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus . Arthritis Rheum1989; 32: 1107-1118 .
26.
Petri M , Buyon J , Skovron ML , Kim M . Reliability of SELENA SLEDAI and flare as clinical trial outcome measures [abstract] . Arthritis Rheum1997; 40 (No 9 Suppl): S218-S218 .
27.
Kalunian KC, Buyon J, Merrill JT et al. Guidelines for use of the SLEDAI 1999; submitted.
28.
Strand V , Gladman D , Isenberg D et al. Outcome measures to be used in clinical trials in systemic lupus erythematosus . J Rheumatol1999; 26 (2): 490-497 .
29.
Smolen JS , Strand V , Cardiel M et al. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains . J Rheumatol1999; 26 (2): 504-507 .
